

# Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy - Study Design of the APPEAR-C3G Trial



## Methods and cohort



APPEAR-C3G Trial  
RCT, double blinded  
Phase III  
(NCT04817618)



38 centers  
18 countries




n = 68

### Criteria

- ✦ Biopsy proven C3G
- ✦ Low C3 levels (<77 mg/dl)
- ✦ Proteinuria ( $\geq 1.0$  g/g)
- ✦ eGFR  $\geq 30$  mL/min/1.73m<sup>2</sup>

## Intervention



## Objectives (Iptacopan vs placebo at 6 months)

### Primary



To demonstrate superiority of iptacopan on proteinuria (UPCR) reduction

### Secondary



Improvement of baseline eGFR



Effect on patient reported fatigue



Reduction of glomerular inflammation



Evaluate safety and tolerability

C3G Complement 3 glomerulopathy eGFR estimated glomerular filtration rate UPCR Urine protein creatinine ratio

**KI REPORTS**  
Kidney International Reports

Bomback A et al, 2022

Visual abstract by:  
Krithika Mohan, MD, DNB

@krithicism

**Conclusion** This study aims to demonstrate the clinical benefits of alternative pathway inhibition with iptacopan in C3 glomerulopathy.

Visual abstract supported by Novartis